Share

Press Releases

October 18, 2021
Dr. Catherine Knupp Culminates Remarkable Career of Advancing Animal Care with Breakthrough New Products and Continuous Innovations Zoetis Inc. (NYSE:ZTS) today announced the appointment of Robert J. Polzer, PhD, as Executive Vice President and President of Research & Development for the company, effective Jan. 1, 2022. Polzer currently serves as Senior Vice President of Global Therapeutics for Zoetis and joined the company in 2015 after spending more than 20 years in R&D leadership roles at Pfizer. Polzer will become a member of the Zoetis Executive team and report to Chief Executive Officer Kristin Peck. Dr. Catherine Knupp, DVM, MS, and EVP and President of Research and Development at Zoetis, plans to retire after a remarkable career of building the organizational talent and capabilities that have made Zoetis the innovative leader in animal health. (Photo: Zoetis) Polzer will succeed current EVP and President of R&D, Dr. Catherine Knupp, DVM, MS, who will remain head of ...
October 14, 2021
The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a fourth quarter 2021 dividend payable to holders of the company’s common stock of $0.25 per share. The dividend is to be paid on Wednesday, December 1, 2021, to holders of record on Friday, October 29, 2021. About Zoetis As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After nearly 70 years innovating ways to predict, prevent, detect, and treat animal illness, Zoetis continues to stand by those raising and caring for animals worldwide - from livestock farmers to veterinarians and pet owners. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics, and technologies make a difference in over 100 countries. In 2020, Zoetis generated revenue of $6.7 billion with ~11,300 employees. For more, visit www.zoetis.com . DISCLOSURE NOTICES Forward-Looking Statements: This press release contains ...
October 5, 2021
First-of-its-kind technology now offers both digital cytology and artificial intelligence (AI) fecal testing in a single platform, furthering company commitment to diagnostics that drive animal care PARSIPPANY, N.J. – October 5, 2021 – Zoetis today announced its latest innovation in diagnostics with the addition of digital cytology testing to its Vetscan Imagyst™ platform, which was introduced in September 2020. With the launch of digital cytology, Vetscan Imagyst now offers a network of expert remote pathologists in addition to AI technology for fecal testing. As Zoetis continues to develop additional innovative applications for Vetscan Imagyst, it plans to seamlessly integrate even more new capabilities into the platform, helping veterinarians provide the best possible care for dogs and cats. This latest digital cytology application for Vetscan Imagyst provides rapid access to expert clinical pathologists for the assessment of samples consisting of cells from blood, internal organs, ...
October 5, 2021
Increasing production capacity for veterinary monoclonal antibodies to support the ongoing commercial demand and pipeline of future veterinary mAbs DUBLIN, IRELAND – Oct. 5, 2021– Zoetis Inc., the world’s leading animal health company, is expanding its manufacturing and development facility in Tullamore, Ireland, which should significantly increase its capacity for producing veterinary monoclonal antibodies (mAbs) over time. These therapeutic biopharmaceuticals are the latest breakthroughs in animal medicine from Zoetis’ innovative pipeline of products. The announcement was welcomed by the Tánaiste and Minister for Enterprise Trade and Employment Leo Varadkar TD who said, “The decision of Zoetis to further extend its footprint here and expand its Tullamore facility is really fantastic news and a testament to the existing team. The Midlands has a wealth of talent to draw from and I wish the company the very best with this latest development.” The planned expansion of the existing ...
September 30, 2021
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Nov. 4, 2021. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2021 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations . Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on Nov. 4, 2021. About Zoetis As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After nearly 70 years innovating ways to predict, prevent, detect, and treat animal illness, Zoetis continues to stand by those raising and caring for animals worldwide - from livestock farmers to ...
September 28, 2021
Seramount (formerly Working Mother Media) recognized Zoetis for forward-thinking programs and benefits related to parental leave, family support and job flexibility Kristy Earley-Murray, Strategic Veterinarian, Named Zoetis’ Working Mother of the Year Chip Dorsey, Business Development VP, Named Zoetis’ First-Ever Working Father of the Year For the eighth year in a row, Zoetis has been named one of Seramount’s 100 Best Companies (previously known as the Working Mother 100 Best Companies list). The company was also named to Seramount’s Best Companies for Dads list for the first time. Both awards reflect Zoetis’ commitment to providing colleagues with a range of family-friendly benefits and flexible work arrangements. “The COVID-19 pandemic continues to present challenges and uncertainty for all of our colleagues, especially our working parents and caregivers,” said Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Global Operations at Zoetis. “We believe it is ...
September 13, 2021
Zoetis Inc. (NYSE:ZTS) will participate in the Jefferies Virtual Pet Care Summit on Thursday, Sept. 16, 2021. Glenn David, Executive Vice President and Group President, International Operations, Aquaculture, BioDevices and Pet Insurance, will represent the company and respond to questions from analysts. He is scheduled to present at 11:00 a.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations . A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After nearly 70 years innovating ways to predict, prevent, detect, and treat animal illness, Zoetis continues to stand by those raising and caring for animals worldwide - from livestock farmers to veterinarians ...
August 5, 2021
Reports Revenue of $1.9 Billion, Growing 26%, and Net Income of $512 Million, or $1.07 per Diluted Share, Increasing 36% and 35%, Respectively, on a Reported Basis for Second Quarter 2021 Reports Adjusted Net Income of $566 Million, or Adjusted Diluted EPS of $1.19, for Second Quarter 2021 Delivers 22% Operational Growth in Revenue and 28% Operational Growth in Adjusted Net Income for Second Quarter 2021 Increases Full Year 2021 Revenue Guidance to $7.625 - $7.700 Billion and Diluted EPS of $4.09 - $4.19 on a Reported Basis, or $4.47 - $4.55 on an Adjusted Basis Zoetis Inc . (NYSE: ZTS) today reported its financial results for the second quarter of 2021 and increased its guidance for full year 2021. The company reported revenue of $1.9 billion for the second quarter of 2021, an increase of 26% compared with the second quarter of 2020. Net income for the second quarter of 2021 was $512 million, or $1.07 per diluted share, an increase of 36% and 35%, respectively, on a reported basis. ...
August 4, 2021
Increases Zoetis’ range of products, with potential for greater global expansion Provides future growth opportunities, manufacturing capacity, and increased capabilities in Australian animal health market Strengthens Zoetis’ anaesthetic portfolio for companion animals with addition of Alfaxan ® Continues Zoetis’ strategic use of capital to achieve long-term growth Zoetis Inc. (NYSE: ZTS) today announced it has entered into an agreement to acquire Jurox, a privately held animal health company, which develops, manufactures and markets a wide range of veterinary medicines for treating companion animals and livestock. Jurox’s operations are based in Australia, with additional regional offices and subsidiaries in New Zealand, U.S., Canada and the UK. Financial terms of the transaction are not being disclosed. Once completed, the acquisition of Jurox will bring Zoetis a range of important products primed for greater global expansion; a valuable animal health portfolio, including Alfaxan ® , ...
July 2, 2021
Oakland Zoo is first zoo to protect large cats and bears against COVID-19 using the experimental vaccine uniquely formulated for animals Zoetis is donating more than 11,000 doses of its experimental COVID-19 vaccine to help protect the health and well-being of more than 100 mammalian species living in nearly 70 zoos, as well as more than a dozen conservatories, sanctuaries, academic institutions and government organizations located in 27 states. The vaccine has been authorized for experimental use on a case by case basis by the United States Department of Agriculture (USDA) and the appropriate state veterinarians. The vaccine deployment to dozens of zoos follows Zoetis’ response in January to a request from the San Diego Zoo following confirmed cases of COVID-19 in the gorillas at the San Diego Zoo Safari Park. Receiving their first shipment of vaccines on June 29, Oakland Zoo in Northern California quickly assembled their veterinary and animal care teams to begin vaccinations of ...
June 30, 2021
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Aug. 5, 2021. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2021 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations . Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on August 5, 2021. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses in advancing care for animals. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines, diagnostics, technologies and services, including biodevices, genetic tests and ...
June 10, 2021
After four years of co-funding from Zoetis and the Bill & Melinda Gates Foundation, smallholder farms improve productivity thanks to new diagnostics, vaccines and treatments Livestock health and farmers’ livelihoods have been dramatically improved in Sub-Saharan Africa, following the administration of 1.7 billion doses of vaccines and medicines and over 650,000 diagnostic tests through Zoetis’ African Livestock Productivity and Health Advancement (A.L.P.H.A.) initiative, now in its fourth year. The initiative - founded in 2017 with a $14 million grant from the Bill & Melinda Gates Foundation – is dedicated to improving animal health and livelihoods in the region by increasing access to quality veterinary vaccines, medicines and services, diagnostic laboratory networks, and animal health training. In four years of activity, the company has made significant progress in establishing the infrastructure and training to improve the state of animal health and productivity. Ten new ...
June 3, 2021
Zoetis Foundation commits $35 million over 5 years to advance opportunities for veterinarians and farmers Donated over $6 million in community support during 2020 with nearly 10% of that supporting COVID-19 relief efforts On track to 100% renewable energy and RE100 commitment with 8.8% renewable electricity sourced Zoetis today published its 2020 Sustainability Report “Our Journey Toward a Better World” describing its commitment to continued disclosure on environmental, social and governance (ESG) topics and progress toward the company’s Driven to Care long-term sustainability aspirations. The report highlights the company’s journey to champion a healthier, more sustainable future through specific commitments to Communities, Animals and the Planet; these commitments build on Zoetis’ purpose and help achieve the United Nations’ Sustainable Development Goals (SDGs). Complementing the report is a comprehensive ESG Appendix , an update from the company’s baseline disclosure published in ...
June 1, 2021
The range of products are designed to help veterinarians address common – and sometimes debilitating – injuries in horses PARSIPPANY, NEW JERSEY – June 1, 2021 – Zoetis Inc., the world’s leading animal health company, announced that it will expand its portfolio of equine horse care products, with the addition of Pro-Stride ® APS , Restigen ® PRP and CenTrate ® BMA,  a range of devices designed to help address injuries common in horses that may cause lameness. Equine lameness as a result of musculoskeletal pain, particularly osteoarthritis, is one of the top reasons for veterinary evaluation 1 and can have significant physical, economic and quality-of-life impact to both horse and owner. Horse joint health care is an increasingly important segment in equine medicine 2 . These stall-side devices offer the opportunity to harness a horse’s own natural healing mechanisms to manage joint and soft tissue ailments. A major benefit of using these devices is the ability for easy stall-side ...
May 27, 2021
Zoetis Inc. (NYSE:ZTS) will participate in the William Blair 41 st Annual Growth Stock Conference on Wednesday, June 2, 2021. Glenn David, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 12:20 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations . A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After nearly 70 years innovating ways to predict, prevent, detect, and treat animal illness, Zoetis continues to stand by those raising and caring for animals worldwide - from livestock farmers to veterinarians and pet owners. The company’s leading portfolio ...
May 24, 2021
Zoetis Inc. (NYSE:ZTS) will participate in the Stifel 2021 Virtual Jaws & Paws Conference on Thursday, June 3, 2021. Kristin Peck, Chief Executive Officer, will represent the company and respond to questions from analysts. She is scheduled to present at 2:00 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations . A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After nearly 70 years innovating ways to predict, prevent, detect, and treat animal illness, Zoetis continues to stand by those raising and caring for animals worldwide - from livestock farmers to veterinarians and pet owners. The company’s leading portfolio and pipeline of medicines, ...
May 20, 2021
Zoetis Inc . (NYSE:ZTS) today announced the results of shareholder voting at its 2021 Annual Meeting of Shareholders and provided details on its third quarter 2021 dividend. Virtual Annual Meeting of Shareholders Zoetis held a virtual annual meeting today, with Chairman Michael B. McCallister presiding over the business portion of the meeting and shareholder voting. Chief Executive Officer Kristin Peck discussed the company’s strong performance in 2020 resulting from the resilience of Zoetis colleagues and the essential nature of the company’s animal health products. “We achieved operational revenue growth of 9% and grew adjusted net income 10% operationally in 2020. We also generated a strong cash flow that enabled us to protect jobs, ensure the safety of our colleagues, maintain reliable supply for customers, continue investing in our long-term growth plans, and return excess capital to our shareholders,” said Peck. Peck also discussed several highlights from the last year, ...
May 11, 2021
Zoetis Inc. (NYSE:ZTS) today announced leadership changes that will accelerate its long-term growth strategy in key markets and add new talent to its executive team. Glenn David, Executive Vice President and Chief Financial Officer (CFO) for Zoetis, has been named Executive Vice President and Group President, overseeing International Operations and other business units, effective June 1, 2021. In addition, the company announced Wetteny Joseph will join Zoetis as Executive Vice President and Chief Financial Officer, reporting to CEO Kristin Peck, and assume responsibility for the oversight of the company’s financial management, planning, and business development group, effective June 1, 2021. “Glenn’s record of success at Zoetis, plus his deep knowledge of our operations and the animal health industry, make him the ideal leader to drive Zoetis’ next phase of global growth in international markets, aquaculture, biodevices and pet insurance,” said Chief Executive Officer Kristin Peck. ...
May 6, 2021
Reports Revenue of $1.9 Billion, Growing 22%, and Net Income of $559 Million, or $1.17 per Diluted Share, Increasing 32% and 33%, Respectively, on a Reported Basis for First Quarter 2021 Reports Adjusted Net Income of $603 Million, or Adjusted Diluted EPS of $1.26, for First Quarter 2021 Delivers 21% Operational Growth in Revenue and 34% Operational Growth in Adjusted Net Income for First Quarter 2021 Increases Full Year 2021 Revenue Guidance to $7.500 - $7.625 Billion and Diluted EPS of $4.08 - $4.19 on a Reported Basis, or $4.42 - $4.51 on an Adjusted Basis Zoetis Inc . (NYSE: ZTS) today reported its financial results for the first quarter of 2021 and increased its guidance for full year 2021. The company reported revenue of $1.9 billion for the first quarter of 2021, an increase of 22% compared with the first quarter of 2020. Net income for the first quarter of 2021 was $559 million, or $1.17 per diluted share, an increase of 32% and 33%, respectively, on a reported basis. Adjusted ...
March 31, 2021
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 6, 2021. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Glenn David will review first quarter 2021 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations . Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on May 6, 2021. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses in advancing care for animals. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines, diagnostics, technologies and services, including biodevices, genetic tests and ...
March 10, 2021
Only stand-alone animal health company to align its sustainability targets with United Nations’ Sustainable Development Goals Commitments made to advance veterinary education and access to care; invest in innovation to support sustainable livestock farming Joins RE 100 with commitment to achieve 100% Renewable Energy use by 2050 Zoetis Inc. (NYSE:ZTS) today announced its long-term sustainability goals, which build on the company’s purpose to nurture the world and humankind by advancing care for animals. Under the banner Driven to Care , Zoetis brings to life its specific commitments to Communities, Animals and the Planet, including support of 10 of the 17 United Nations’ Sustainable Development Goals (SDGs). With operations in 45 countries, Zoetis has the global reach and capabilities to champion a healthier, more sustainable future for all. “While purpose has been a driving factor for Zoetis throughout our history, formalizing our goals and commitments integrates sustainability as a ...
February 24, 2021
Zoetis Inc. (NYSE:ZTS) will participate in the Cowen 41 st Annual Health Care Conference on Monday, March 1, 2021. Kristin Peck, Chief Executive Officer, will represent the company and respond to questions from analysts. She is scheduled to present at 1:20 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations . A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses in advancing care for animals. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines, diagnostics, technologies and services, including biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people ...
February 22, 2021
Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Securities 2021 Animal Health Summit Virtual Forum on Thursday, Feb. 25, 2021. Glenn David, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 7:50 a.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations . A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses in advancing care for animals. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines, diagnostics, technologies and services, including biodevices, genetic tests and precision livestock farming. Zoetis ...
February 22, 2021
Solensia is the first injectable monoclonal antibody (mAb) licensed for alleviation of pain associated with osteoarthritis (OA) in cats Solensia works as a monthly treatment targeting Nerve Growth Factor (NGF), a key player in OA pain European Commission Marketing Authorization for a similar product in dogs, Librela®,was received in November 2020 Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the marketing authorization for Solensia ® (frunevetmab), a new feline osteoarthritis treatment to alleviate pain. Osteoarthritis in cats is a very prevalent condition 1 , existing in 40% of cats, and may generate pain and limit a cat’s comfort and quality of life if not treated. Solensia works differently from current treatment options by targeting Nerve Growth Factor (NGF), a key player in osteoarthritis (OA) pain. 1,2 It functions like naturally occurring antibodies, with minimal involvement of the liver or kidneys in their metabolism and elimination process, ...
February 16, 2021
For Fourth Quarter 2020, Zoetis Reports Revenue of $1.8 Billion, Growing 8%, and Net Income of $359 Million, or $0.75 per Diluted Share, on a Reported Basis Reports Adjusted Net Income of $438 Million, or Adjusted Diluted EPS of $0.91, for Fourth Quarter 2020 Delivers 9% Operational Growth in Revenue and 3% Operational Growth in Adjusted Net Income for Fourth Quarter 2020 For Full Year 2020, Zoetis Reports Revenue of $6.7 Billion, Growing 7%, and Net Income of $1.6 Billion, or $3.42 per Diluted Share, on a Reported Basis Reports Adjusted Net Income of $1.8 Billion, or Adjusted Diluted EPS of $3.85 for Full Year 2020 Delivers 9% Operational Growth in Revenue and 10% Operational Growth in Adjusted Net Income for Full Year 2020 Provides Full Year 2021 Revenue Guidance of $7.400 - $7.550 Billion, with Diluted EPS of $4.02 - $4.14 on a Reported Basis, or $4.36 - $4.46 on an Adjusted Basis Zoetis Inc . (NYSE: ZTS) today reported its financial results for the fourth quarter and full year ...
February 10, 2021
The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a second quarter 2021 dividend payable to holders of the company’s common stock of $0.25 per share. The dividend is to be paid on Tuesday, June 1, 2021, to holders of record on Wednesday, April 21, 2021. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion with approximately 10,600 employees. For more information, visit www.zoetis.com . DISCLOSURE NOTICES Forward-Looking Statements: This ...
February 9, 2021
Zoetis Inc . (NYSE: ZTS), the global leader in animal health, today announced that it has been named one of America’s Best Midsize Employers by Forbes Magazine for the fifth time. “At Zoetis, our colleagues drive our success and shape our reputation as a top employer,” said Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Global Operations. “We continue to build a diverse and inclusive culture - based on our Core Beliefs – where everyone can thrive, both personally and professionally. We are proud to consistently be recognized by Forbes as one of America’s Best Midsize Employers, and we thank our colleagues for recommending Zoetis as a great place to work.” Forbes determined its America’s Best Employers list based on an independent survey among a sample of 50,000 American employees working for companies with at least 1,000 people in their U.S. operations. The willingness to recommend one's own employer was used as the most important factor in the assessment. ...
January 28, 2021
Joins the ranks of 767 major U.S. businesses that received top marks in the HRC Foundation’s Annual Assessment of LGBTQ Workplace Equality Zoetis Inc . (NYSE: ZTS) today announced that it received a score of 100 percent on the Human Rights Campaign Foundation’s 2021 Corporate Equality Index (CEI), the nation’s foremost benchmarking survey and report measuring corporate policies and practices related to LGBTQ workplace equality. This is the first time Zoetis participated in the CEI and the company’s first external recognition of its dedication to LGBTQ+ individuals. Strong Policies Promote an LGBTQ+-Friendly Workplace The high marks scored by Zoetis in the CEI reflect the company’s focus on Diversity, Equity and Inclusion (DE&I) , which includes strong policies and programs that promote an LGBTQ+-friendly workplace, including: Enhanced parental leave for all new parents in the U.S., including for adoptions, fathers and same sex partners; A new colleague resource group, Pride at ...